Filter posts

BIO Answers FAQs on Human Genome Editing

Genome editing has been a hot topic in drug discovery research recently, as CRISPR-based preclinical …

Benefiting from Innovative Clinical Trial Designs

Clinical trial success rates have been known to be low for some time now, but …

Does Big Company M&A Impact Small Company M&A?

Over the last few years, we have seen significant consolidation among the large drug manufacturers, …

Improving Oncology Clinical Trials

The 18th Annual BIO CEO & Investor Conference kicked off with a panel focused on oncology …

2015 FDA Approvals: Highest Levels in Over a Decade

2015 was a blockbuster year for FDA approvals of novel new medicines, many of them …

Haves and Have Nots in Biotech Venture Capital

Recent data from the BIO Industry Analysis team tells a story of “haves and have-nots” …

State of the Industry for Emerging Therapeutic Companies

Emerging therapeutic companies are at their strongest point in a decade. In our new report …

Ten Years of Therapeutic Venture Capital

What therapeutic areas have received the most funding in private drug companies over the last …

Therapeutic Licensing and M&A Deals

Licensing deals for therapeutic candidates in 2013 dropped to the lowest volume in at least …

Debunking the Biotech Bubble Talk

The Nasdaq Biotechnology Index (NBI) has been on a wild ride in 2014 with a …